-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule.
SUMMARY:
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during March 2012. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable.
DATES:
This rule is effective May 17, 2012.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, email: george.haibel@fda.hhs.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
FDA's Center for Veterinary Medicine (CVM) is adopting use of a monthly Federal Register document to codify approval actions for NADAs and abbreviated ANADAs. CVM will no longer publish a separate rule for each action. This approach will allow a more efficient use of available resources.
In this document, FDA is amending the animal drug regulations to reflect the original and supplemental approval actions during March 2012, as listed in table 1 of this document. FDA is also informing the public of the availability of environmental review documents required under the National Environmental Policy Act (NEPA), where applicable. For actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA) may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.Start Printed Page 29217
Table 1—Original and Supplemental NADAs and ANADAs Approved During March 2012
NADA/ANADA Sponsor New animal drug product name Action 21 CFR Section FOIA summary NEPA review 118-980 Elanco Animal Health, A Division of Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285 MONTEBAN (narasin) Type A medicated article Supplement increasing the upper dose limit for narasin in broiler feed 558.363 Yes Environmental assessment (EA)/Finding of no significant impact (FONSI). 111-636 Pharmacia & Upjohn Co., a Division of Pfizer, Inc., 235 East 42d St., New York, NY 10017 LINCOMIX (lincomycin hydrochloride) Soluble Powder Supplement adding an indication for control of American foulbrood in honey bees 520.1263c Yes Categorically excluded (CE).1 200-421 Hospira, Inc., 275 N. Field Dr., Lake Forest, IL 60045 Ceftiofur for Injection (ceftiofur sodium) Sterile Powder Original approval of generic copy of NADA 140-338 522.313c Yes CE. 200-455 Cross Vetpharm Group, Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland TYLOMED-WS (tylosin tartrate) Soluble Powder Supplement adding an indication for control of porcine proliferative enteropathies 520.2640 Yes CE.1 200-473 Huvepharma AD, 33 James Boucher Blvd., Sophia 1407, Bulgaria TYLOVET Soluble (tylosin tartrate) Supplement adding an indication for control of porcine proliferative enteropathies 520.2640 Yes CE.1 1 The Agency has determined under 21 CFR 25.33 that this action is CE from the requirement to submit an EA or an environmental impact statement (EIS) because it is of a type that does not individually or cumulatively have a significant effect on the human environment. This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
Start List of SubjectsList of Subjects
21 CFR Part 510
- Administrative practice and procedure
- Animal drugs
- Labeling
- Reporting and recordkeeping requirements
21 CFR Parts 520 and 522
- Animal drugs
21 CFR Part 558
- Animal drugs
- Animal feeds
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, and 558 are amended as follows:
Start PartPART 510—NEW ANIMAL DRUGS
End Part Start Amendment Part1. The authority citation for 21 CFR part 510 continues to read as follows:
End Amendment Part Start Amendment Part2. In § 510.600, in the table in paragraph (c)(1), alphabetically add an entry for “Hospira, Inc.”; and in the table in paragraph (c)(2), numerically add an entry for “000409” to read as follows:
End Amendment PartNames, addresses, and drug labeler codes of sponsors of approved applications.* * * * *(c) * * *
(1) * * *
Firm name and address Drug labeler code * * * * * Hospira, Inc., 275 North Field Dr., Lake Forest, IL 60045 000409 * * * * * (2) * * *
Drug labeler code Firm name and address * * * * * 000409 Hospira Inc., 275 North Field Dr., Lake Forest, IL 60045. * * * * * PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part3. The authority citation for 21 CFR part 520 continues to read as follows:
End Amendment Part Start Amendment Part4. In § 520.1263c, revise paragraph (b) and add paragraph (d)(3) to read as follows:
End Amendment PartLincomycin powder.* * * * *(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter for use as in paragraph (d) of this section.
(1) No. 000009 for use as in paragraph (d) of this section.
(2) Nos. 046573, 054925, 061623, and 076475 for use as in paragraphs (d)(1) and (d)(2) of this section.
* * * * *(d) * * *
(3) Honey bees—(i) Amount. Mix 100 milligrams lincomycin with 20 grams confectioners'/powdered sugar and dust over the top bars of the brood chamber once weekly for 3 weeks.
(ii) Indications for use. For the control of American foulbrood (Paenibacillus larvae).
(iii) Limitations. The drug should be fed early in the spring or late in the fall and consumed by the bees before the main honey flow begins to avoid contamination of production honey. Complete treatments at least 4 weeks before main honey flow.
5. In § 520.2640, revise paragraph (b) introductory text to read as follows:
End Amendment PartTylosin.* * * * *(b) Sponsors. See Nos. 000986, 016592, and 061623 in § 510.600(c) of this chapter.
* * * * *PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part6. The authority citation for 21 CFR part 522 continues to read as follows:
End Amendment Part Start Amendment Part7. In § 522.313c, revise paragraphs (b), (e)(2)(ii), (e)(3)(ii), (e)(4)(ii), and (e)(8)(i) to read as follows:
End Amendment PartCeftiofur sodium.* * * * *(b) Sponsors. See Nos. 000009, 000409, and 068330 in § 510.600(c) of this chapter.
* * * * *(e) * * *
(2) * * *
(ii) Indications for use. For treatment of bovine respiratory disease (shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. Also, for the treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.
* * * * *(3) * * *
(ii) Indications for use. For treatment of sheep respiratory disease (sheep pneumonia) associated with Mannheimia haemolytica and Pasteurella multocida.
* * * * *(4) * * *
(ii) Indications for use. For treatment of caprine respiratory disease (goat pneumonia) associated with Mannheimia haemolytica and Pasteurella multocida.
* * * * *(8) * * *
(i) Amount. 1.0 mg/lb (2.2 mg/kg) body weight by subcutaneous injection. Treatment should be repeated at 24-hour intervals for 5 to 14 days.
* * * * *PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
End Part Start Amendment Part8. The authority citation for 21 CFR part 558 continues to read as follows:
End Amendment Part Start Amendment Part9. In § 558.363, revise paragraph (d)(1)(i) introductory text to read as follows:
End Amendment PartNarasin.* * * * *(d) * * *
(1) * * *
(i) Amount per ton. Narasin, 54 to 90 grams.
* * * * *Dated: May 7, 2012.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2012-11937 Filed 5-16-12; 8:45 am]
BILLING CODE 4160-01-P
Document Information
- Comments Received:
- 0 Comments
- Effective Date:
- 5/17/2012
- Published:
- 05/17/2012
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final rule.
- Document Number:
- 2012-11937
- Dates:
- This rule is effective May 17, 2012.
- Pages:
- 29216-29218 (3 pages)
- Docket Numbers:
- Docket No. FDA-2012-N-0002
- Topics:
- Administrative practice and procedure, Animal drugs, Animal feeds, Labeling, Reporting and recordkeeping requirements
- PDF File:
- 2012-11937.pdf
- Supporting Documents:
- » Freedom of Information Summary ANADA 200-543 Cefpodoxime Proxetil
- » Freedom of Information Summary ANADA 200-491, Loxicom (meloxicam)
- » Freedom of Information Summary ANADA 200-485, Meloxicam Injection (meloxicam)
- » Freedom of Information Summary NADA 200-496 96% Solution Growing chickens, turkeys and laying hens
- » Freedom of Information Summary NADA 200-534 Melengestrol acetate plus monensin USP plus tylosin phosphate
- » Freedom of Information Summary NADA 141-068 BAYTRIL 100 Injectable Solution
- » Freedom of Information Summary NADA 141-346 OroCAM
- » Freedom of Information Summary NADA 141-344 VERAFLOX Suspension for Cats
- » Freedom of Information Summary ANADA 200-466 SPARMECTIN Plus Clorsulon
- » Freedom of Information Summary NADA 141-342 ALFAXAN
- CFR: (5)
- 21 CFR 510.600
- 21 CFR 520.2640
- 21 CFR 558.363
- 21 CFR 520.1263c
- 21 CFR 522.313c